<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04827069</url>
  </required_header>
  <id_info>
    <org_study_id>PCD-DHEC73543-16-001</org_study_id>
    <nct_id>NCT04827069</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate Clifutinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia(AML)</brief_title>
  <official_title>A Phase I, Multi-center, Open,Single Arm, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Clifutinib Besylate(HEC73543) in Relapsed or Refractory Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and&#xD;
      pharmacodynamics (PD) of Clifutinib Besylate in Relapsed/refractory AML patients with&#xD;
      FLT3-ITD mutation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a multi-center , open-label, single arm study conducted in 2 parts. Dose-escalation&#xD;
      part: Subjects will receive oral Clifutinib Besylate once on C0D1.After 3 days,they will&#xD;
      receive Clifutinib Besylate once daily repeatedly until disease progression or unacceptable&#xD;
      toxicity occurs, each cycle is defined as 28 days.&#xD;
&#xD;
      Expansion part:Expansion cohort might be set to further investigate the safety and efficacy&#xD;
      of Clifutinib Besylate at or lower MTD dose recommended by dose-escalation part.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 8, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Arm 1:10 mg Arm 2:20 mg Arm 3:40 mg Arm 4:55 mg Arm 5:70 mg</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>day 1-28</time_frame>
    <description>Safety and Tolerability assessed through adverse events to determine maximum tolerated dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>On day 1,8,15,22,28</time_frame>
    <description>to assess the pharmacokinetic profile in patients with AML</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax)</measure>
    <time_frame>On day 1,8,15,22,28</time_frame>
    <description>to assess the pharmacokinetic profile in patients with AML</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration time curve</measure>
    <time_frame>On day 1,8,15,22,28</time_frame>
    <description>to assess the pharmacokinetic profile in patients with AML</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite CR rate</measure>
    <time_frame>up to 18 months</time_frame>
    <description>CR + CRi +CRMRD-</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>up to 18 months</time_frame>
    <description>The time from receive CR / CRi/CRMRD-/PR to relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>up to 18 months</time_frame>
    <description>CR + CRi +CRMRD- + PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>up to 18 months</time_frame>
    <description>From the first time taking experimental drug to treatment failure or progression or relapse or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 18 months</time_frame>
    <description>From the first time taking experimental drug to death</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clifutinib Besylate:10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clifutinib Besylate:20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clifutinib Besylate:40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clifutinib Besylate:55 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clifutinib Besylate:70 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clifutinib Besylate</intervention_name>
    <description>receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm 5</arm_group_label>
    <other_name>HEC73543</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented acute myeloid leukemia according to World Health Organization（WHO）&#xD;
             criteria(excluding acute promyelocytic leukemia), with FLT3-ITD gene&#xD;
             mutation,refractory after common or enhanced chemotherapy or relapse.&#xD;
&#xD;
          -  ECOG performance status of 0-1.&#xD;
&#xD;
          -  Subjects must have adequate organ function and meeting all of the following laboratory&#xD;
             review before enrollment：&#xD;
&#xD;
               -  Lood routine examination: WBC≤2000/mm3;&#xD;
&#xD;
               -  Liver function: Alanine aminotransferase (ALT) and Aspartate transaminase (AST)&#xD;
                  ≤2.5×upper limit of normal(ULN); serum bilirubin ≤ 1.5 × ULN;&#xD;
&#xD;
               -  Renal function: Serum creatinine ≤ 1.5×ULN, or the creatinine clearance (CrCl)≥&#xD;
                  60 mL / min calculated by the Cockcroft-Gault formula;&#xD;
&#xD;
               -  Electrolyte: serum potassium≥3.0mmol/L; serum calcium≥2.0 mmol/L;serum&#xD;
                  magnesium≥0.5 mmol/L;&#xD;
&#xD;
               -  Coagulation function:fibrinogen≥1.0g/L; activated partial thromboplastin time(&#xD;
                  APTT)≦ULN+10s; prothrombin time(PT)≤ULN+3s.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received FLT3 inhibitors within 4 weeks prior to the administration;&#xD;
&#xD;
          -  Received hematopoietic stem cell transplantation within2 months prior to the&#xD;
             administration or received immunosuppressor beceause of GVHD;&#xD;
&#xD;
          -  Chemotherapy, immunotherapy, radiotherapy, or major surgery within 4 weeks prior to&#xD;
             administration;&#xD;
&#xD;
          -  Nitrosourea and mitomycin chemotherapy within 6 weeks prior to the administration;&#xD;
&#xD;
          -  Have taken live vaccines within 4 weeks prior to /or concurrent with the&#xD;
             administration;&#xD;
&#xD;
          -  Have received a trial investigational product, or participated in other clinical&#xD;
             trials within 4 weeks prior to administration;&#xD;
&#xD;
          -  Documented promyelocytic leukemia (t (15; 17) (q22; q11) and / or promyelocytic&#xD;
             leukemia(PML)/retinoic acid receptor alpha (RARa) positivity found in the chromosome,&#xD;
             variant acute promyelocytic leukemia;&#xD;
&#xD;
          -  With myeloid sarcoma or invasion of central nervous system;&#xD;
&#xD;
          -  NCI CTCAE 4.03 ≥ 2 grade of arrhythmia, or corrected QT interval(QTc )&gt; 450 ms ;&#xD;
             patients with a history of torsion or congenital QT prolonged syndrome; active&#xD;
             infectious disease judged by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Jin, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Jin, Doctor</last_name>
    <phone>0571-87236685</phone>
    <email>jiej0503@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the First Affiliated Hospital,College of Medicine,Zhejiang University</name>
      <address>
        <city>Hanzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Jin, Doctor</last_name>
      <phone>0571-87236685</phone>
      <email>jiej0503@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

